Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon Partners With Voluntis On Digital Therapeutics For Diabetics

Insulia Digital Tool To Be Paired With Biocon Insulins

Executive Summary

The global collaboration agreement pairs Biocon’s insulins with Voluntis’s Insulia, the first digital therapeutic with regulatory clearance for insulin-dependent type 2 diabetes patients. Biocon further reveals plans for a complete digital therapeutics portfolio for patients

You may also be interested in...



Asia Deal Watch: Perceptive Launches LianBio With “China-Centric” Strategy

Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.

Biocon Sees Recovery In Biosimilars

Biocon’s biosimilars business sees bounce-back in first quarter of fiscal 2021, with the US business witnessing gradually improving demand. The Indian company also sees potential for improved affordability in the US.

Biocon Sees Recovery In Biosimilars, Scope To Address Affordability In US

Biocon’s biosimilars business sees bounce-back in first quarter of fiscal 2021, with the US business witnessing gradually improving demand. The Indian company also sees potential for improved affordability in the US.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150096

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel